Life Competence - the first global picture on the EU-funded health research

It is now possible to have a global picture of which research organisations and which research areas were funded by the European Commission during the 2001-2006 years (6th European Research Framework Programme). The data has been generated from an online webbased database of competences, supported through an EU specific support action.

The project has been implemented by AVEDAS AG, Germany, Karolinska Institutet, Sweden and EuropaBio, Belgium. It contains all the health related projects funded by the EU during the last Research Framework Programme, as well as the principal organisations participating in these projects. The aim of this database is to increase transparency and accessibility of research competences in Europe, both for Europeans (in a recent Eurobarometer, 70% of them expressed their interest in health research) but also for other nationalities interested in participating in the European Health Research effort.

In the European Research Programme going from 2001 to 2006 (FP6), the part of the programme focussing on health research was major with its budget of € 2.4 billion supporting 680 projects. It was shared between different research areas with about 50% of the projects and budget dedicated to disease oriented research areas. Cancer is the area receiving most support with 123 projects, about 18 % of projects partly or entirely focussed on cancer, with 22 % of the budget (€ 539 million). Other important research areas are AIDS/HIV, Stem Cell Research, Diabetes, Diagnostics, Vaccines and Drug design.

An important policy in the EU is to support competitiveness by encouraging cooperation of academia and clinicians with industry, and especially with small and medium-sized enterprises (SMEs). Out of 2.438 unique partners in health research projects, 853 are from the private sector, of which 365 SMEs (15%). It means that around 20 % of the total number of SMEs in the Health sector are participating in the EU programme. The majority of partners in the programme are academic.

Another important policy in European research is international cooperation. Participation from countries outside Europe and its associated states represents about 5% of partners of health projects. The highest number of participations are from China, Russia, US and South Africa. Within Europe, about 6% of the partners are from the 12 new EU-member states and 7% of the partners are from the states associated to the EU with science and technology cooperation agreements that involved contributing to the framework programme budget.

It is expected that the 'LifeCompetence' database will have many positive implications for the Health research society in Europe and for worldwide cooperations, e.g. increased knowledge transfer, better partnerships and more efficient management of research programmes and research organisations, as well as providing a transparent information on the resources invested in funding health research at the European level.

For further information, please visit:
http://www.lifecompetence.eu

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...